PharmaShots Weekly Snapshot (29 Oct-03 Nov,2018)


  1. Illumina Acquires Pacific Biosciences for ~$1.2B with its Sequel SMRT Technology

Published: 02 Nov, 2018 | Tags: Illumina, Acquires, Pacific Biosciences, ~1.2B, Sequel SMRT Technology


  1. AbbVie Exercises its Option to License Agreement for BioArctic’s Alpha-Synuclein Antibody Portfolio, Signed in 2016

Published: 02 Nov, 2018 | Tags: AbbVie, Exercises, Option, License, Agreement, BioArctic’s, Alpha-Synuclein Antibody Portfolio, Signed, 2016

  1. Health Canada Approves Novartis’ Combination Therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) to Treat patients with BRAF V600 Mutation Melanoma

Published: 01 Nov, 2018 | Tags: Health Canada, Approves, Novartis’ ,Combination Therapy, Tafinlar (dabrafenib) and Mekinist (trametinib) ,Treat, BRAF V600, Mutation Melanoma

  1. Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

Published: 01 Nov, 2018 | Tags: Aileron Therapeutics, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Enters, Clinical Collaboration, Treat, Pediatric Patients, Cancer

  1. Vertex Receives EU’s MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mutations in CFTR gene

Published: 01 Nov, 2018| Tags: Vertex, Receives, EU’s, MAA, Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor), Treat, CF, aged ≥12yrs., mutations, CFTR gene

  1. Sanofi and Denali Therapeutics Collaborates to Develop & Commercialize Clinical Candidates for Neurology and Inflammatory Disorders

Published: 01 Nov, 2018 | Tags: Sanofi, Denali Therapeutics, Collaborates, Develop, Commercialize, Molecules, Neurology, Inflammatory Disorders, DNL747, DNL758

  1. Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

Published: 01 Nov, 2018 | Roche, Receives, EU, Approval, Venclyxto (venetoclax), MabThera (rituximab) ,Treat, Adults, CLL, P-III MURANO study

  1. Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14 study for CLL patients

Published: 01 Nov, 2018 | Tags: Roche, Reports, Results, Venclexta/Venclyxto plus Gazyva/Gazyvaro, P-III CLL-14 study, CLL patients


  1. Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

Published: 31 Oct, 2018 | Tags: Sandoz, Hymiroz, (adalimumab-adaz), Receives, the US FDA, Approval, Treatment, Chronic Autoimmune Diseases, ADACCESS study, , PsA, AS, adult CD, UC, Ps

  1. Gilead Signs Global Research Collaboration with Tango to Develop & Commercialize Targeted Immuno-Oncology Therapies

Published: 31 Oct, 2018 | Tags: Gilead, Signs, Global, Research, Collaboration, Tango, Develop, Commercialize, Targeted, Immuno-Oncology, Therapies

  1. Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors

Published: 30 Oct, 2018 | Tags: Henry Ford Health System,Signs, Development, Commercialization ,Agreement, G3 Pharma, Galectin-3 inhibitors, HFpEF

  1. Biocardia, CellProThera & SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction

Published: 30 Oct, 2018 | Tags: Biocardia, CellProThera , SlngXpand, Collaborates, Develop, Commercialize ,CD34+ Stem cells ,Singapore, Myocardial Infarction

  1. Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events in Adults with T2D

Published: 30 Oct, 2018 | Tags: Janssen’s (J&J), Invokana, (canagliflozin), Receives, FDA, Approval, MACE events, Adults, T2D

  1. Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development of Therapeutic Targets

Published: 30 Oct, 2018 | Tags: Roche, Licenses, Halozyme’s, ENHANZE Technology, ~190M, Development, Therapeutic, Targets, Rituxan, Rituxan Hycela & Herceptin

  1. Mirati Therapeutics Announces IND Submission of MRTX849 to Treat NSCLC & CRC

Published: 29 Oct, 2018 | Tags: Mirati, Announces, IND Submission, MRTX849, Treat, NSCLC, CRC


  1. Gilead Reports Results of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1

Published: 29 Oct, 2018 | Tags: Gilead, Reports, Results, Biktarvy, Bictegravir, Emtricitabine, Tenofovir Alafenamide, P-III Study 1490, HIV-1

  1. Astellas’ Xtandi (enzalutamide) Receives EU’s Approval for Men with High-Risk Non-Metastatic

Published: 29 Oct, 2018 | Tags: Astellas, Xtandi, (enzalutamide), Receives, EU, Approval, High-Risk, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

      18.  AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

Published: 30 Oct, 2018 | Tags: AstraZeneca, Divests, Rights, Nexium, Vimovo, Grunenthal

19.  Jazz Receives FDA Approval for Xyrem’s (sodium oxybate) sNDA to Treat Cataplexy or Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy

Published: 29 Oct, 2018 | Tags: Jazz, Receives, FDA, Approval, Xyrem’s (sodium oxybate), sNDA ,Treat ,Cataplexy, Excessive Daytime Sleepiness, Pediatric ,Narcolepsy

20. ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5 Candidate (now QR-1123)

Published: 29 Oct, 2018 | Tags: ProQR, Signs, Worldwide, Exclusive, License, Agreement , Ionis, IONIS-RHO-2.5 Candidate, (QR-1123)

21.  Novartis & Pfizer Enters into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

Published: 28 Oct, 2018 | Tags: Novartis, Pfizer, Enters, Clinical Development, Collaboration,Treat, Non-Alcoholic Steatohepatitis (NASH), PF-05221304, PF-06865571 , PF-06835919, US FDA

22.  Lilly Signs a Global Research and License Collaboration with Dicerna for ~$550M

Published: 29 Oct, 2018 | Tags: Lilly, Signs, Global, Research, License, Collaboration, Dicerna, ~$550M, GalXC RNAi technology

23. Esperion Reports Completion of Bempedoic Acid in Global P-III LDL-C Development Program for Patients with ASCVD or HeFH

Published: 28 Oct, 2018 | Tags: Esperion, Reports, Completion, Bempedoic Acid,Global, P-III LDL-C Development Program ,ASCVD or HeFH

24. Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH

Published: 28 Oct, 2018 | Tags: Esperion, Reports, Results, Bempedoic Acid, P-III Study 2 or 1002-047, ASCVD, HeFH



Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post